What is the new injection for MS? Introducing Ocrevus Zunovo and Emerging Therapies
•
3 min read
In September 2024, the FDA approved Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq), a new injection for MS that is administered as a twice-a-year, 10-minute subcutaneous treatment. This offers a significantly quicker option for patients compared to the original intravenous infusion and expands access to treatment.
